Roche Highlights its Response to COVID-19 Pandemic

Shots:

• On Mar 19, 2020, the company initiates the global P-III study in collaboration with BARDA to assess the efficacy of Actemra/RoActemra (tocilizumab, IV) + SOC vs PBO + SOC in hospitalized patients with severe COVID-19 pneumonia
• Roche facilitates the delivery and production of Actemra and is working continuously to increase the availability of COVID 19-tests as its test has received FDA’s EUA for its SARS-CoV-2 test
• Roche is working with governments across the globe to work closely with industry to keep manufacturing and supply running to tackle the pandemic

Click here ­to­ read full press release/ article | Ref: Roche | Image: Pinterest